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The short-lived messenger nitric oxide (NO) regulates key 
functions of adult skeletal muscle, such as the activity of neuro-
muscular synapses, excitation–contraction coupling, vasodilation, 
glucose uptake, mitochondrial function and biogenesis, glycoly-
sis, and phosphocreatine breakdown (Wang et al., 1995; Balon 
and Nadler, 1997; Clementi and Meldolesi, 1997; Wolosker et al., 
1997; Bredt, 1998; Stamler and Meissner, 2001; Eu et al., 2003; 
Nisoli et al., 2004). The possibility that NO plays a role in skele-
tal myogenesis is suggested by the observations that it partici-
pates in satellite cell activation (Anderson, 2000; Tatsumi et al., 
2002) and that its synthesizing enzymes, the NO synthases 
(NOSs), are developmentally regulated and may contribute to 
the myogenic program activated by IGF-II (Lee et al., 1994; 
Blottner and Luck, 1998; El Dwairi et al., 1998; Kaliman et al., 
1999). The precise role of NO in myogenesis and the signaling 
pathways acting downstream of it are, however, not known.
In the present study, we investigated these aspects, both 
in vitro and in vivo, at different phases of myogenesis. Our re-
sults show that NO directly stimulates myoblast fusion through 
the up-regulation of follistatin, defi  ning for the fi  rst time a link 
between NO and another key player in adult and embryonic 
myogenesis. We also found that the action of NO is limited 
to a defi  ned time window and is mediated through a tightly 
regulated activation of guanylate cyclase and generation of 
cyclic guanosine monophosphate (cGMP), a physiological ef-
fector of NO (Moncada et al., 1991). Maintenance of cGMP 
signaling by treatment with 8 Br-cGMP leads to an increased 
fusion process with generation of hypertrophic myotubes and 
myofi  bers in vitro and in vivo. Overall, our results indicate a 
pivotal role of NO/cGMP in regulating myoblast fusion during   
muscle development.
Results
Exogenous and endogenous NO increase 
satellite cell fusion in vitro in a 
speciﬁ  c time window
To study the effects of NO on myoblast differentiation and fu-
sion, satellite cells isolated from newborn mice and plated at low 
density (6 × 10
3 cells/cm
2) were maintained for 48 h in growth 
medium and then switched to the differentiating medium in the 
presence or absence of increasing concentrations of the NO 
donor (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]dia
zen-1-ium-1,2-diolate] (DETA-NO), which releases NO con-
stantly and at defi  ned concentrations (Clementi et al., 1998), or 
N
ω-nitro-l-arginine methyl ester (l-NAME), which is a broad 
spectrum inhibitor of NOS (Moncada et al., 1991). The fusion 
index was measured after 24, 48, or 72 h. As shown in Fig. 1 A, 
DETA-NO increased, whereas l-NAME decreased, the fu  -
sion index in concentration-dependent ways. These effects were 
Figure 1.  NO induces fusion of satellite cells. (A) Satellite cells 
from newborn mice were maintained for 48 h in growth medium 
and then switched to the differentiation medium in the presence 
or absence of increasing concentrations of DETA-NO or L-NAME. 
Cells were stained after 72 h with the anti–sarcomeric myosin MF20 
mAb and the nuclear dye Hoechst. The fusion index indicates the 
number of nuclei in myosin-expressing cells with more than two 
nuclei versus the total number of nuclei measured. (B) Same as A, 
except that satellite cells were exposed or not (NT) to single con-
centrations of DETA-NO (50 μM) and L-NAME (5 mM). The fusion 
index was measured after 24, 48, or 72 h. (C) Representative im-
ages of B showing the effects of 50 μM DETA-NO and 5 mM 
L-NAME on satellite cell fusion after 72 h with respect to those 
of untreated controls. The staining for myosin is in green (FITC). 
(D) 5 mM L-NAME and 50 μM DETA-NO were added to differen-
tiating satellite cells at the indicated time points. The fusion index 
was assessed after 72 h (n = 6). (E and F) NOS activity, mea-
sured as conversion of L-arginine into L-citrulline (E; n = 4), and 
NOS Iμ and III expression, measured by Western blotting with 
speciﬁ  c mAbs (F), in the course of satellite cell differentiation in 
vitro as described in A. The Western blot shown here is represen-
tative of four reproducible experiments. (G) MyoD, PCNA, and 
GAPDH expression measured by Western blotting with speciﬁ  c 
mAbs in satellite cells exposed or not for 24 h in differentiation 
medium to either 50 μM DETA-NO or 5 mM L-NAME. Results are 
representative of four reproducible experiments. (H) Percentage 
of mononucleated cells, binucleated cells, and multinucleated 
myotubes expressing sarcomeric myosin (myo) in satellite cells 
exposed or not for 72 h in differentiation medium to either 50 μM 
DETA-NO or 5 mM L-NAME as described in A. Values are ex-
pressed as percentage over those observed in NT. Error bars rep-
resent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus NT.
Bar, 250 μm.
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specifi  c because the corresponding amine, DETA, did not yield 
signifi  cant effects and the action of l-NAME was inhibited by 
5 mM l-arginine (unpublished data). The stimulation by DETA-
NO and the inhibition by l-NAME were clearly detected after 
24 h and were increased throughout the differentiation program, 
becoming statistically signifi  cant after 48 and 72 h of culture 
(Fig. 1, B and C). At 72 h, almost no fusion events were ob-
served among myosin-expressing satellite cells in the presence 
of 5 mM l-NAME (Fig. 1 C). The fact that the effects of DETA-
NO and l-NAME on fusion were already present after 24 h of 
treatment suggests that these events took place at an early stage 
in the differentiation program. To establish the time window of 
the NO action, 5 mM l-NAME and 50 μM DETA-NO (yield-
ing a concentration of 120 ± 5 nM, n = 5, measured with a 
NO electrode; Clementi et al., 1998) were added to differen-
tiating satellite cells at different time points. The fusion index 
was assessed after 72 h. As shown in Fig. 1 D, both DETA-
NO and l-NAME were maximally effective in enhancing and 
preventing fusion, respectively, when added at the beginning 
of the differentiation process. The compounds were progres-
sively less effective when added at later time points and almost 
completely ineffective when added after 16 h. Consistently, 
we found that the differentiation process was accompanied by 
an early increase in NOS activity that peaked at 8 h and de-
creased thereafter, returning to basal levels after 48 h (Fig. 1 E). 
We found that satellite cells express the endothelial (NOS III) 
and muscular (NOS Iμ) variants of the neuronal NOS. The lev-
els of expression of NOS III and Iμ were unchanged throughout 
the differentiation process (Fig. 1 F), indicating that the changes 
in NOS activity were the consequences of activation and inhibi-
tion of enzyme activity and not of changes in protein expres-
sion. NOS II expression was never detected throughout the time 
window analyzed (unpublished data).
Satellite cells cultured in vitro are asynchronous, with a 
small portion of them still persisting as undifferentiated cells 
even after several days in differentiating medium (Cossu et al., 
1980; Ontell and Kozeka, 1984). The increased fusion of satel-
lite cells triggered by NO may be attributable to an effect of this 
messenger on the process itself or secondary to NO-dependent 
recruitment of the undifferentiated cells into terminal differen-
tiation (Anderson, 2000). This should result in an increase in 
MyoD expression and a concomitant decrease in cell prolifera-
tion. To discriminate between these possibilities, we examined 
the effects of NO on these processes. As shown in Fig. 1 G, ex-
posure of satellite cell cultures for 24 h to either 5 mM l-NAME 
or 50 μM DETA-NO changed neither the expression of the 
myogenic marker MyoD nor that of the DNA polymerase δ co-
factor (PCNA), which is expressed during the S phase of the 
cell cycle. We consistently found no increases in either prolifer-
ation, measured by counting the number of nuclei in all cells, or 
Figure 2.  The effect of NO on satellite cell fusion 
depends on cGMP generation. (A and B) Satellite cells 
were maintained for 48 h in growth medium and then 
switched to the differentiation medium for up to 72 h. 
(A) Guanylate cyclase activity, measured as formation of 
cGMP after stimulation with or without (NT) 50 μM 
DETA-NO or 5 mM L-NAME administered for 30 min at 
the indicated time points (n = 4). (B) Expression of soluble 
guanylate cyclase and GAPDH (loading control), mea-
sured by Western blotting with mAbs speciﬁ   c for the 
α and β subunits of the enzyme. Results are representative 
of four reproducible experiments. (C) Satellite cell differen-
tiation was performed as described in A for 72 h in the 
presence of an increasing concentration of 8 Br-cGMP. 
The fusion index was measured as described in Fig. 1 
(n  = 4). (D and E) Same as in C except that satellite cell 
differentiation was performed for 72 h in the presence or 
absence of 5 mM L-NAME, 50 μM DETA-NO, 3 μM 
ODQ, or 3 mM 8 Br-cGMP in various combinations as de-
tailed in the key to the panels. Fusion index was measured 
as described in Fig. 1. Representative images are shown in 
E. Anti–sarcomeric myosin MF20 mAb is in green (FITC), 
and the nuclear dye Hoechst in blue. **, P < 0.01 ver  -
sus NT; ***, P < 0.001 versus NT; †, P < 0.001 versus 
8 Br-cGMP–treated cells (n = 6). Error bars represent SEM. 
Bar, 200 μm.
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Figure 3.  Persistence of cGMP leads to fusion-induced muscle hypertophy at different stages of muscle development. (A–C) Satellite cells from newborn 
mice were plated at high density (3 × 10
4 cells/cm
2), maintained for 48 h in growth medium, and switched to the differentiation medium in the presence 
or absence of 50 or 150 μM DETA-NO or 0.3, 1.0, or 3.0 mM 8 Br-cGMP. After 48 h, cells were either stained with the anti–sarcomeric myosin MF20 
mAb (green, FITC) and the nuclear dye Hoechst (blue) or processed for Western blot analysis. (A) Representative images of four reproducible experiments 
(3 mM 8 Br-cGMP and 50 μM DETA-NO). 10× magniﬁ  cation. (B) Percentage of nuclei containing >12 nuclei, calculated as depicted in Fig. 1. *, P < 0.05;
***, P < 0.001 versus untreated cells (NT; n = 4). (C) Sarcomeric myosin (myosin) and GAPDH expression, determined by Western blotting (one out of 
four reproducible experiments). (D and E) PSM explants from MLC1/3F-nLacZ E9.5 embryos were differentiated for 4 d in the presence or absence of 50 
or 150 μM DETA-NO, 5 mM L-NAME, or 1 or 3 mM 8 Br-cGMP. (D, left) Immunoﬂ  uorescence using the anti–sarcomeric myosin MF20 mAb (green, FITC). 
The myogenic nuclei are labeled by X-Gal staining (dark blue). (right) Same ﬁ  elds as in the left panels, but the X-Gal staining is merged with Hoechst stain-
ing (light blue), labeling all nuclei. Arrows demarcate multinucleated myotubes, which are absent in untreated explant cultures and frequent in cultures 
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the number of nuclei present in myosin-positive cells (unpub-
lished data). This excludes the possibility that the formation of 
hypernucleated myotubes with increased size was a consequence 
of an increased number of undifferentiated myogenic cells re-
cruited to terminal differentiation, suggesting that NO acts directly 
as an inducer of myoblast fusion.
The process whereby myogenic cells generate myofi  bers 
is the consequence of the initial fusion between two myoblasts 
and the subsequent fusion of new cells to the initial two-cell 
myotube (Charge and Rudnicki, 2004). As shown in Fig. 1 H, 
5 mM l-NAME increased, whereas 50 μM DETA-NO decreased, 
the percentage of mononucleated cells. In addition, DETA-NO 
increased the formation of binucleated cells and multinucleated 
myotubes, whereas l-NAME reduced the number of myotubes.
The results reported in Fig.1 demonstrate that the activity 
of NOS and generation of NO are tightly regulated during satel-
lite cell differentiation and that NO triggers and enhances 
fusion without infl  uencing other events in the differentiation 
program of these cells. The fact that exogenous NO is not effec-
tive when NOS is inhibited suggests that NO signaling is regu-
lated not only at the level of its generation by NOS but also 
downstream of it.
The effect of NO on satellite cell fusion 
depends on a controlled generation 
of cGMP
We next analyzed the dependence of the effects of NO on the 
activation of guanylate cyclase and generation of cGMP, an im-
portant signaling event mediating several physiological actions 
of NO (Moncada et al., 1991). As shown in Fig. 2 A, differentia-
tion of satellite cells in culture is accompanied by generation of 
cGMP, occurring in a 4–24-h time window, consistent with the 
time window of the effect of NO (Fig. 1 E). The generation of 
cGMP was NO dependent because exposure of differentiating 
cells to 5 mM l-NAME or 50 μM DETA-NO administered for 
30 min at each of the time points indicated in Fig. 2 A inhibited 
or enhanced, respectively, generation of cGMP. Of importance, 
the ability of DETA-NO to increase the cyclic nucleotide was sig    -
nifi  cantly higher when it was administered during the fi  rst 12 h 
of the differentiation process. It thereafter declined to a point 
similar to that of nondifferentiated cells (Fig. 2 A, compare time 
72 h with time 0). These results suggest that in satellite cells 
sensitivity of guanylate cyclase to NO is regulated and its acti-
vation favored in the initial phases of differentiation. Because 
the levels of expression of the two guanylate cyclase subunits 
α and β did not change with time (Fig. 2 B), it appears that such 
regulation occurs through posttranslational events.
To assess the role of cGMP generation in satellite cell fu-
sion, we studied the effect of the cell membrane–permeant 
cGMP analogue 8 Br-cGMP (0.3–5 mM) and the guanylate cy-
clase inhibitor 1H-(1,2,4) oxadiazolo [4,3-α]quinoxalin-1-one 
(ODQ; 3 μM), which were administered in the 4–24-h time 
window in which these cells generate cGMP. Satellite cell 
  fusion was measured after 72 h. As shown in Fig. 2 (C–E),
8 BrcGMP and ODQ mimicked the effects of DETA-NO and 
l-NAME, respectively. In addition, the fusogenic effect of 
DETA-NO, although insensitive to l-NAME, was abrogated 
by ODQ. ODQ, however, did not affect fusion stimulated by
8 Br-cGMP. These results clearly indicate that the effect of NO 
on satellite cell fusion depends on activation of guanylate 
cyclase and generation of cGMP.
The results depicted in Fig. 1 suggest that NO signaling is 
regulated not only at the level of its generation by NOS but also 
downstream of it. The results in Fig. 2, showing the cGMP de-
pendence of the effect of NO and the time-dependent changes in 
the sensitivity of guanylate cyclase to NO, indicate that this reg-
ulatory step downstream of NOS activity is at the level of gua-
nylate cyclase.
Persistence of cGMP during satellite cell 
differentiation and embryonic myogenesis 
leads to hypertrophy
We examined whether the tight regulation of the NO/cGMP 
  signaling during the differentiation process is needed to pre    vent 
nonphysiological overgrowth of the myotube. We investigated 
this possibility by both in vitro and in vivo approaches. To mimic 
deregulated cGMP signaling in satellite cells, differentiation was 
performed in the continuous presence of 0.3–3 mM 8 Br-cGMP. 
In addition, satellite cells were plated at high density (3 × 10
4 
cells/cm
2) to favor fusion. After 48 h of differentiation under 
these conditions, satellite cells gave rise to distinctly hypertro-
phic myotubes (Fig. 3 A). Hypertrophy induction was concen-
tration dependent, as it was the increase in myosin expression 
(Fig. 3 C). The myotubes in 8 Br-cGMP–treated cultures were 
considered to be hypertophic because their mean nuclei number 
and fi  ber dimension (Fig. 3 B) and the total amount of myo-
sin (Fig. 3 C) were signifi  cantly higher compared with controls 
and were increased by the cyclic nucleotide in a concentration-
  dependent way. Such hypertrophy and increase in myosin were 
not observed in satellite cells differentiated in the presence of 
50–300 μM DETA-NO, even at the higher concentrations tested 
(Fig. 3, A–C; and not depicted).
Satellite cell differentiation occurs through signaling 
pathways similar but not identical to those observed during em-
bryonic skeletal muscle development (Charge and Rudnicki, 
2004). We therefore evaluated the role of the NO–cGMP path-
way and of its deregulation in embryonic and fetal myogenesis. 
Presomitic mesoderm (PSM) or the most caudal somites (I–III) 
from the myosin light chain promoter 1/3 fast (MLC1/3F)–
nLacZ 9.5-d postcoitum transgenic mouse embryos, in which 
treated with 3 mM 8 Br-cGMP. Results shown are representative of four reproducible experiments. (E) Fusion index, measured in the same conditions 
as detailed in Fig. 1. *, P < 0.05; ***, P < 0.001 versus NT (n = 4). (F) X-Gal staining of MLC1/3F-nLacZ embryos, developed in the absence (left) 
or presence (right) of 8 Br-cGMP (3 g/kg body weight) administered through the pregnant mother from E10.5 to either E12.5 (top and middle) or 
E15.5 (bottom). The areas selected in red in the top panels are enlarged in the middle panels. Arrows show larger and more elongated ﬁ  bers, indi-
cating an increased level of myogenesis. Results are representative of three reproducible experiments. Error bars represent SEM. Bars: (A) 150 μm; 
(D) 125 μm; (F, top) 1.5 mm; (F, middle) 500 μm; (F, bottom) 1 mm.
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the LacZ gene is under the transcriptional control of MLC1/3F 
(Kelly et al., 1995), were grown as explants in cultures in the 
presence or absence of 50–300 μM DETA-NO, 1–3 mM 
8 Br-cGMP, or 5 mM l-NAME. After only 2 d in cultures, dif-
ferentiated mononucleated myocytes emerged from the PSM 
explants, and these increased in number after an additional 2 d 
(Fig. 3, D and E). Neither 50–300 μM DETA-NO nor l-NAME 
had relevant effects on the time of appearance and the number 
of myocytes after 4 d at any concentration tested (Fig. 3, D and 
E; and not depicted); in contrast, 3 mM 8 Br-cGMP triggered 
formation of myotubes, an event that does not occur physiologi-
cally in PSM explant cultures (Cossu and Biressi, 2005), indi-
cating that the cyclic nucleotide was able to break the fusion 
restriction in the PSM and myotome (Fig. 3 D). The effect of 
8 Br-cGMP was concentration dependent (Fig. 3 E). Similar 
  results were observed in somite explants (unpublished data).
To study myogenesis during late embryonic and fetal de-
velopment, MLC1/3F-nLacZ pregnant females were treated 
with or without 8 Br-cGMP (3 g/kg body weight) from gesta-
tion day 10 to either 12.5 or 15.5. Embryos were then recov-
ered, and myogenic cells were revealed by LacZ staining. As 
shown in Fig. 3 F, 8 Br-cGMP–treated embryos showed en-
hanced LacZ staining, indicating an increased level of myogen-
esis at both time points considered. These results clearly indicate 
that continuous presence of cGMP increases myotube size and 
results in muscle hypertrophy and that the tight regulation of its 
concentration is required for a normal myogenic process.
The NO/cGMP signaling in myogenesis is 
mediated by the up-regulation of follistatin 
expression through transcriptional 
activation mediated by NFAT/ CREB/MyoD
We were interested in identifying the molecular effectors of the 
NO/cGMP signaling and to assess whether molecules known 
to play a role in muscle hypertrophy, such as IGF-I (Musaro 
and Rosenthal, 1999; Rommel et al., 2001), interleukin 4 
(IL-4; Horsley et al., 2003), or follistatin (Iezzi et al., 2004), 
were involved.
We thus performed semiquantitative RT-PCR on RNA 
isolated from differentiated satellite cells, PSM explants, or 
muscle from embryonic and fetal stages that were treated or un-
treated with 3 mM 8 Br-cGMP, 50 μM DETA-NO, or 5 mM 
l-NAME using primer specifi  c for IGF-I, IL-4, follistatin, myo-
statin, and skeletal muscle–specifi  c MLC1/3F (Fig. 4 A). In par-
allel, we examined the expression of IGF-I, IL-4, follistatin, 
myostatin, and sarcomeric myosin heavy chain by Western blot-
ting (Fig. 4 B). Quantitative assessment and statistical analy-
ses of the results obtained are shown in Fig. S1 (available at 
http://  www.  jcb.  org/  cgi/  content/  full/  jcb.  200507083/  DC1).  
Although l-NAME had no effects in all conditions, we 
observed an increased level of myosin light chain transcripts 
and protein from 8 Br-cGMP– and DETA-NO–treated cultures 
and embryos. In satellite cells, this was accompanied by a 
marked increase in follistatin expression at both the mRNA and 
protein levels. Of importance, in PSM explants and embryos, 
follistatin expression was increased only in the presence of 
8 Br-cGMP, whereas DETA-NO had no signifi  cant  effect 
(Fig. 4 and Fig. S1). Myostatin protein levels were not signifi  -
cantly affected, even if there was a decrease in mRNA levels. 
We also observed that the mRNA and protein levels of IGF-I 
were slightly increased by 8 Br-cGMP. These changes, how-
ever, were not signifi  cant (Fig. 4 and Fig. S1). No changes in the 
levels of IL-4 were detected (unpublished data). These results 
suggest that increased generation of follistatin is relevant to the 
NO/cGMP signaling during myoblast differentiation.
Follistatin has recently been described to be a central me-
diator of the fusogenic effects exerted by deacetylase inhibitors 
on myoblast fusion into preformed myotubes through a path-
way distinct from those used by either IGF-I or IL-4 (Iezzi et al., 
2004). In particular, regulation of follistatin by deacetylase in-
hibitors, such as trichostatin A (TSA), appeared to be coopera-
tively activated by MyoD, nuclear factor of activated T cells 
(NFAT), and cAMP response element binding protein (CREB; 
Iezzi et al., 2004).
To investigate whether the NO–cGMP pathway acti-
vated the follistatin promoter by the same pathway, we used 
the myogenic cell line C2C12, which was also used in Iezzi et 
al. (2004). Similar to satellite cells, C2C12 myoblasts gave rise 
to hypertrophic myotubes when cultured in the constant pres-
ence of 8 Br-cGMP (Fig. 5, A and B). This was accompanied by 
Figure 4.  Effects of NO/cGMP on gene expression at different stages of 
muscle development. (A) RT-PCR using primers speciﬁ  c for MLC3, IGF-I, 
myostatin, follistatin, and GAPDH on mRNA obtained from satellite cells, 
E9.5 PSM explants, muscle tissues dissected from E12.5 and E15.5 mouse 
embryos, differentiated in presence of L-NAME, 50 μM DETA-NO, or 
8 Br-cGMP (3 mM or 3 g/kg body weight). Results are representative of 
three reproducible experiments. (B) Expression of sarcomeric myosin, IGF-I, 
follistatin, myostatin, and GAPDH determined by Western blotting using 
speciﬁ  c antibodies on satellite cells and muscle tissue from E15.5 embryos, 
differentiated in the presence of 5 mM L-NAME, 50 μM DETA-NO, or 
8 Br-cGMP (3 mM or 3 g/kg body weight). Results are representative of 
three reproducible experiments.
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concentration-dependent increases in the levels of follistatin 
(Fig. 5 C). To study the effect on follistatin transcription, the fol-
listatin promoter linked to the luciferase gene (Fs-Luc) was trans  -
fected in C2C12 cells (Iezzi et al., 2004). 8 Br-cGMP acti-
vated transcription of Fs-Luc (Fig. 5 D). To establish whether 
the activation of follistatin promoter by cGMP was mediated by 
MyoD, CREB, and NFAT, Fs-Luc–transfected C2C12 were dif-
ferentiated in the presence of 8 Br-cGMP and/or transfected 
with the negative regulator of MyoD; Id1 (Iezzi et al., 2004); or 
the dominant-negative form of CREB, A-CREB (Herzig et al., 
2001), or VIVIT, which is a peptide that blocks NFAT-dependent 
transcription (Aramburu et al., 1999). We observed that the 
8 Br-cGMP–dependent activation of Fs-Luc was inhibited in 
the presence of any of these inhibitors (Fig. 5 D). Thus, NFAT, 
MyoD, and CREB mediate the effects of 8 Br-cGMP on fol-
listatin transcription. Previous studies in other cell types showed 
that CREB and NFAT are activated by cGMP through a protein 
kinase G–dependent phosphorylation (Gudi et al., 1996; Pilz 
and Casteel, 2003; Gonzalez Bosc et al., 2004). Accordingly, we 
found that 3 μM each of two structurally unrelated protein  kinase 
G inhibitors, KT5823 and 8-(chlorophenylthio)guanosine-3′,
5′- cyclic monophosphorothioate ([Rp]-8-pCPT-cGMPS; Smo-
le    nski et al., 1998), prevented the induction of Fs-Luc transcrip-
tion by cGMP (Fig. 5 D). In smooth muscle, cGMP may act 
through protein kinase A, an enzyme that plays a role in selected 
myogenic pathways (Cornwell et al., 1994; Chen et al., 2005). 
The possible involvement of protein kinase A in mediating the 
effects of cGMP, however, was excluded by the lack of inhibi-
tory effects by 3 μM of the protein kinase A inhibitors KT5720 
and (Rp)-8-pCPT-cAMPS (Fig. 5 D).
We then studied whether the muscle hypertrophic effect of 
8 Br-cGMP was exclusively dependent on the activation of fol-
listatin transcription or whether IGF-I was also involved, in view 
of the small but detectable changes in the levels of IGF-I tran-
scripts induced by 8 Br-cGMP (Fig. 4). We cultured both satellite 
and C2C12 cells in differentiating condition in the presence of 
8 Br-cGMP and of either antibodies directed against follistatin to 
neutralize its activity (Iezzi et al., 2004) or the phosphatidylino-
sitol 3′ kinase inhibitor LY294002, which inhibits IGF-I signal-
ing in muscle (Ibarra et al., 2004). In addition, we used the small 
interference RNA approach already shown to silence follistatin 
expression in C2C12 cells (Iezzi et al., 2004). The neutralizing 
follistatin antibodies inhibited the action of 8 Br-cGMP without 
signifi  cant effects on its own in both satellite (Fig. 5, A and E) 
and C2C12 cells (Fig. 5 B). Cell transfection with the small 
|interfering RNA against follistatin consistently inhibited the 
  effect of 8 Br-cGMP in C2C12 cells (Fig. S2, available at 
http://www.jcb.org/cgi/content/full/jcb.200507083/DC1). These 
results indicate that the effect of cGMP is mostly mediated by 
the activation of follistatin. Consistent with this, LY294002 did 
not modify the effects of 8 Br-cGMP while inhibiting those of 
IGF-I in both satellite cells and C2C12 (Fig. 5 F and not de-
picted). To assess the cell specifi  city of the effect of cGMP on 
follistatin, we investigated whether it also increased follistatin 
expression in cells belonging to nonmuscle lineages, namely 
  embryonic carcinoma cells (P19) undergoing neuronal differen-
tiation, adult (NIH 3T3) and embryonic (10 T1/2) fi  broblast 
cell lines, mesoangioblast-derived smooth muscle progenitors 
(D351; Brunelli et al., 2004), and primary cultures of cardiomy-
ocytes. 8 Br-cGMP had no effects on follistatin levels in any 
of these cells, whereas it consistently increased follistatin in-
duction in C2C12 cells used as control (Fig. S3, available at 
http://www.jcb.org/cgi/content/full/jcb.200507083/DC1).
Discussion
Skeletal muscle mass growth and maintenance is controlled 
principally through the regulation of myofi  ber size both dur-
ing embryogenesis and in postnatal life. This regulation occurs 
through two main and distinct mechanisms. One relies on the 
regulation of the cytoplasmic volume associated with individ-
ual myonuclei, and this pathway appears to involve regulation 
of protein synthesis and of protein degradation (Glass, 2003; 
Stitt et al., 2004). The second mechanism involves the control 
of the number of myonuclei within a myofi  ber. In this case, the 
growth of the muscle fi  ber during fetal and postnatal develop-
ment depends on the addition of single cells, embryonic or fetal 
myoblast and satellite cells, respectively, that must be instructed 
when to divide and when to differentiate by either fusing with 
preexisting fi  bers or among themselves to generate a new fi  ber 
(Cossu and Biressi, 2005).
Myoblast fusion is a multiple-step process involving cell 
migration, alignment, recognition, adhesion, and membrane fu-
sion (Wakelam, 1985; Chen and Olson, 2004), and several mol-
ecules have been identifi  ed as playing a role in one or more of 
these processes, including IL-4, IGFs, integrins, and metallo-
proteases (Galliano et al., 2000; Rommel et al., 2001; Horsley 
et al., 2003; Schwander et al., 2003; Yi et al., 2005). The mecha-
nisms and signaling pathways underlying the role of these mol-
ecules controlling myoblast fusion, however, have yet to be 
fully elucidated.
We demonstrate that the generation of NO is crucial to 
myoblast fusion in mammals. We found that the action of NO 
has several important characteristics. (a) It appears to have an 
effect at critical stages of pre- and postnatal muscle develop-
ment life. (b) It works through the same signaling pathway at all 
stages, i.e., activation of guanylate cyclase, with generation of 
cGMP and induction of follistatin. (c) It is specifi  c to the fusion 
process itself because NO did not affect cellular differentiation 
and/or proliferation. This defi  nes for the fi  rst time a common 
trigger for fusion and is the fi  rst evidence indicating that the fu-
sion process may take place through the same activating process 
in both the embryo and the newborn.
Another important aspect of the pathway to muscle fusion 
activated by NO emerging from our results is that it is a regu-
lated process. We have studied it in detail in satellite cells. We 
found that the regulation of NO effects on muscle fusion oc-
curred at two distinct early steps of the signaling cascade, i.e., 
the enzymatic activities of NOS and guanylate cyclase, which 
were regulated in the absence of detectable changes in protein 
levels. The regulation of guanylate cyclase appears to be partic-
ularly important because activation of the enzyme could not be 
increased even by administration of exogenous NO. We have 
not yet identifi  ed which events among the ones proposed to 
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Figure 5.  NO/cGMP increase expression of follistatin. Satellite (A, E, and F) and C2C12 cells (B–D) were differentiated for 48 h in the presence or 
absence (NT) of 8 Br-cGMP (3 mM, where not otherwise indicated), 4 μg/ml anti-follistatin antibody (αFs), 5 μM LY294002, or 10 ng/ml IGF-I in various 
combinations as indicated. (A and B) Representative images of four reproducible experiments after staining with the anti-myosin MF20 mAb (green, FITC) 
and the nuclear dye Hoechst (blue). (C) Same as in B, except that C2C12 cells were lysed and mRNA analyzed by real-time PCR. (D) Same as in B except 
that C2C12 cells were previously transfected with Fs-Luc and transfected with or without Id1, A-CREB, or VIVIT before differentiation or treated with 3 μM 
KT5823, 3 μM KT5720, 3 μM (Rp)-8-pCPT-cGMPS, or 3 μM (Rp)-8-pCPT-cAMPS. Expression of Fs-Luc was quantiﬁ  ed by chemiluminescence. (E and F) 
Satellite cell fusion index in the various conditions. ***, P < 0.001 versus controls; †, P < 0.001 versus 8 Br-cGMP–treated cells (n = 3). Error bars 
represent SEM. Bars: (A) 100 μm; (B) 200 μm.
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  induce desensitization of guanylate cyclase to NO, e.g., phos-
phorylation by protein kinases or even a direct action of NO 
itself (Bellamy et al., 2000; Friebe and Koesling, 2003), play a 
role in the desensitization observed here. The physiological rel-
evance of this event, however, is clear because deregulation of 
cGMP signaling leads to muscle hypertrophy both in satellite 
cells and in the embryo. More strikingly, myoblasts differentiat-
ing from the PSM, known to be incompetent for fusion (Cossu 
and Biressi, 2005), acquire such competence in the presence of 
cGMP, suggesting that the NO–cGMP pathway not only is cru-
cial to stimulating fusion but also may confer competence to it. 
Whether and how this occurs when the mononucleated myo-
cytes of the myotome are incorporated into newly formed pri-
mary fi  bers remains to be studied.
Of the three NOS isoforms, murine (and human) skeletal 
muscles express the constitutive NOS Iμ and III, whereas ex-
pression of the inducible NOS II is clearly detected only in the 
presence of infl   ammation or other pathological conditions 
(Thompson et al., 1996; Stamler and Meissner, 2001). Accord-
ingly, we found that satellite cells and skeletal muscle from em-
bryos (unpublished data) express NOS Iμ and III. However, it is 
conceivable that both enzymes may play a role because both 
NOS Iμ and III are activated by increases in intracellular cal-
cium concentrations, and NOS III is also activated by Akt 
  (Alderton et al., 2001), i.e., signaling events triggered by many 
myogenic stimuli (Guttridge, 2004; Horsley and Pavlath, 2004). 
In addition, no obvious defects in muscle development have 
been reported in NOS I or III knockout mice. Also interesting in 
this respect is the observation that expression and activities of 
both NOS Iμ and III are developmentally regulated (Blottner 
and Luck, 1998; El Dwairi et al., 1998).
The identifi  cation of a link between follistatin and the 
NO/cGMP–dependent fusion adds important new information 
to skeletal muscle biology. Follistatin is a protein that interacts 
with and regulates the biological activities of several TGFβ fam-
ily members, including BMP-4, BMP-7, and activins (Iemura 
et al., 1998; Amthor et al., 2002). Follistatin has been also found 
to block the activity of myostatin, a negative regulator of skeletal 
muscle mass, thus leading to muscle hypertrophy (Lee and 
McPherron, 2001). Therefore, the connection of this protein 
with NO/cGMP identifi  es an endogenously activated pathway 
for follistatin induction that can be activated by many myogenic 
stimuli and defi  nes the role of NO in the process of fusion.
The pathway of follistatin induction by NO/cGMP was 
found to involve MyoD, NFAT, and CREB. Previous work has 
demonstrated that both CREB and NFAT are directly activated 
by NO/cGMP through protein kinase G–dependent phosphory-
lation (Gudi et al., 1996; Fiedler et al., 2002; Pilz and Casteel, 
2003; Gonzalez Bosc et al., 2004). The fact that inhibition of 
protein kinase G prevented follistatin induction by cGMP is con-
sistent with these results and further confi  rms the role of CREB 
and NFAT. We found that expression of MyoD is not affected by 
NO/cGMP; whether this transcription factor is activated by 
NO/cGMP through phosphorylation, similar to other MyoD ac-
tivating stimuli, remains to be established. The biological signif-
icance of each of these transcription factors in mediating the 
effect of NO/cGMP, however, clearly emerges from our results 
because each of them was found to be necessary to follistatin in-
duction. Indeed, specifi  c inhibition of MyoD, NFAT, or CREB 
was suffi  cient to prevent the transcriptional function of cGMP. 
Furthermore, these results suggest that the transcriptional effects 
of NO/cGMP may be more complex than previously envisaged. 
The fact that MyoD, CREB, and NFAT appear to be necessary to 
mediate the transcriptional effect of NO/cGMP resembles the 
situation already described for stimulation of myoblast fusion by 
the deacteylase inhibitor TSA (Iezzi et al., 2004). The similarity 
between the action of TSA and NO/cGMP and the recent evi-
dence showing that TSA is able to up-regulate the expression of 
NOS III in nonendothelial cells (Fish et al., 2005; Gan et al., 
2005) suggests that NO/cGMP is involved in regulating the pro-
cess of acetylation. Interestingly, the effect of NO/cGMP, simi-
lar to that of TSA (Iezzi et al., 2004), was restricted to cells of 
skeletal muscle origin. This cell specifi  city is intriguing, and the 
mechanisms beyond it need to be investigated further.
In conclusion, the link emerging here among the NO/cGMP 
signaling and follistatin induction, an important event during 
prenatal and adult myogenesis, suggests that the role of this mes-
senger may be broader than previously envisaged and at the cross-
road of different signaling pathways central to skeletal muscle 
development and regeneration. The action mediated through 
cGMP/follistatin might also synergize with other known ac-
tions of NO, such as activation of satellite cells (Anderson, 2000; 
Tatsumi et al., 2002). In addition, the cGMP-dependent induc-
tion of follistatin might interact with other cGMP-independent 
actions of NO that may play a role in muscle development, such 
as inhibition of cytochrome c oxidase and control of mitochon-
drial respiration and S-nitros(yl)ation (Stamler and Meissner, 
2001; Moncada and Erusalimsky, 2002).
Materials and methods
Materials
The following reagents were purchased as indicated: ODQ and DETA-NO 
from Alexis Italia, KT5823 and KT5720 from Calbiochem, and (Rp)-8-pCPT-
cGMPS and -cAMPS from Biolog. The following mAbs were purchased as 
indicated: anti–NOS-Iμ and anti–NOS-III mAbs from BD Biosciences, anti–
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mAb from Bio-
genesis, anti-PCNA mAb from Santa Cruz Biotechnology, Inc., anti-MyoD 
mAb from DakoCytomation, anti–sarcomeric myosin MF20 mAb from 
Developmental Studies Hybridoma Bank, anti-follistatin mAb (AF669) from 
R&D Systems, and anti-myostatin (ab996) and anti IGF-I (ab12517) anti-
bodies from AbCAM. In immunoﬂ  uorescence analysis, primary antibodies 
were detected by appropriate FITC-conjugated secondary antibodies 
(Southern Biotechnology Associates, Inc.). In immunoblot analysis, primary 
antibodies were detected by chemiluminescence with appropriate horserad-
ish peroxidase–conjugated secondary antibodies, all purchased from Bio-
Rad Laboratories. Cell culture media and sera were purchased from 
Cambrex. L-[
3H]-arginine and the kits for the enhanced chemiluminescence 
and the cGMP radioimmunoassay were obtained from GE Healthcare. 
Bicinchoninic acid–based assay was obtained from Perbio; C2C12 cells 
were obtained from American Type Culture Collection; and the anti-desmin 
polyclonal antibody, L-NAME, 8 Br-cGMP, LY294002, IGF-I, and the Hoechst 
dye and other chemicals were obtained from Sigma-Aldrich. DETA-NO was 
always prepared fresh by dissolving it at pH 7.4 for 20 min before addition 
to the cell samples. Under these conditions, DETA-NO generates NO con-
stantly and at deﬁ  ned concentrations (Clementi et al., 1998).
Cell cultures
Satellite cells were isolated from 3–5-d-old mice as described previously 
(Cossu et al., 1980) with some modiﬁ  cations. In particular, after 3 d of 
  isolation, proliferating myoblasts were harvested, counted, and plated on 
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  tissue culture plastic dishes coated with 1 mg/ml type I collagen. After 2 d of 
proliferation in growth medium, myogenic cells accounted for >90% of the 
cultures as revealed by anti-desmin immunostaining assay. Preparation show-
ing <90% myogenic cells were discarded. Myoblasts were shifted to differ-
entiating medium in the presence or absence of drugs as indicated in 
Results. Growth medium contained Iscove’s modiﬁ  ed Dulbecco’s medium 
supplemented with 20% FBS, 3% chick embryo extract (Cossu et al., 1987), 
100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μg/ml gentamycin. 
Differ  en  tiation medium contained Iscove’s modiﬁ  ed  Dulbecco’s  medium 
supplemented with 2% horse serum, 100 U/ml penicillin, and 100 μg/ml 
streptomycin. Fusion index was determined as the number of nuclei in sar-
comeric myosin–  expressing cells with more than two nuclei versus the total 
number of nuclei.
C2C12 cells were cultured in DME supplemented with 15% FBS, 
100 U/ml penicillin, and 100 μg/ml streptomycin and differentiated in 
DME supplemented with 2% horse serum, 100 U/ml penicillin, and 100 
μg/ml streptomycin as described previously (Iezzi et al., 2004).
Immunoﬂ  uorescence
Immunoﬂ   uorescence on cells and explants was performed as described 
previously (Brunelli et al., 2004), using the following antibodies: MF20 
(1:3) and anti-desmin (1:400).
Protein extraction and immunoblot analysis
Cells were washed free of medium and solubilized by direct addition of a 
preheated (to 80°C) denaturing buffer containing 50 mM Tris-HCl, pH 6.8, 
2% sodium dodecyl sulfate, and a Complete protease inhibitor cocktail 
(Roche) and immediately boiled for 2 min as previously described (Bulotta 
et al., 2001). Alternatively, muscle tissues from embryos were dissected 
and homogenized in 50 mM Tris/HCl, pH 7.4, 1 mM EGTA, 1 mM EDTA, 
1% Triton X-100, and Complete protease inhibitor cocktail and centrifuged 
(1,000 g) for 20 min at 20°C to discard cellular debris. For secreted pro-
teins analysis, supernatants were collected and concentrated as described 
previously (Corradi et al., 1996). After addition of 0.05% bromophenol 
blue, 10% glycerol, and 2% β-mercaptoethanol, samples were boiled 
again and loaded onto 10% SDS–polyacrylamide gels. After electrophore-
sis, polypeptides were electrophoretically transferred to nitrocellulose ﬁ  lters 
(Schleicher & Schuell) and antigens were revealed by the appropriate 
respective primary and secondary antibodies (Bulotta et al., 2001).
Assay of NOS activity
The time course of NOS activity was assayed in intact cells by measuring the 
conversion of L-[
3H]-arginine into L-[
3H]-citrulline as described previously 
(Bulotta et al., 2001). In brief, the reaction was performed in 145 mM NaCl, 
5 mM KCl, 1 mM MgSO4, 10 mM glucose, 1 mM CaCl2, and 10 mM Hepes, 
pH 7.4. 10 μCi/ml L-[
3H]-arginine (10 μM) was added at various time points, 
and the reaction was stopped after 5 min by washing with ice-cold PBS supple-
mented with 5 mM L-arginine and 4 mM EDTA. 0.5 ml of 100% cold ethanol 
was added to the dishes and left to evaporate before a ﬁ  nal addition of 
20 mM Hepes, pH 6.0. L-NAME–treated cells were run in parallel as control 
of speciﬁ  city. Separation of L-[
3H]-citrulline from L-[
3H]-arginine was performed 
by DOWEX 50X8-400 chromatography. L-[
3H]-citrulline formed was normal-
ized to protein content and evaluated by the bicinchoninic acid procedure.
Measurement of cGMP generation
At each time point, satellite cell cultures were incubated for 30 min at 37°C 
either in growth or in differentiation media with 0.5 mM of the phosphodi-
esterase inhibitor 3-isobutyl-1-methylxanthine supplemented with 50 μM 
DETA-NO, 5 mM L-NAME, or vehicle. The reaction was terminated by 
rapid medium removal and washing with ice-cold PBS and was lysed by 
the addition of ice-cold trichloroacetic acid (ﬁ  nal concentration: 6%). After 
ether extraction, cGMP levels were measured using a radioimmunoassay 
kit and normalized to protein content.
Embryo explants culture
PSM and most of the ﬁ   ve caudal somites were dissected, together with 
fragmentation of the neural tube from MLC1/3F E9.5 embryos, and cul-
tured as explants, as described previously (Cossu et al., 1996). 
Differentiation was continued for 2–4 d in the presence of various drugs, as 
described in Results. Before the immunoﬂ  uorescence assay, X-Gal staining 
was performed according to standard protocols (Brunelli et al., 2003).
Animal treatments
MLC1/3F pregnant females were treated with or without 8 Br-cGMP (3 g/kg 
body weight; administered in drinking water) from gestation day 10 to 
12.5 or 15.5. Embryos were then recovered, and myogenic cells were re-
vealed by X-Gal staining (see Embryo explants culture). Animals were 
housed in the pathogen-free facility at the Stem Cell Research Institute 
(Milan, Italy) and treated in accordance with the European Community 
guidelines and with the approval of the Institutional Ethical Committee.
RT-PCR
1 μg RNA was collected from cells, dissected embryos, or tissues using 
RNeasy mini (or micro) kit (QIAGEN) and was converted into double-
stranded cDNA by reverse transcription using the cDNA synthesis kit 
Thermoscript RT-PCR system (Invitrogen) according to the manufacturer’s in-
structions. cDNA was then ampliﬁ  ed using the following primers: follistatin 
forward, C  T  C  T  T  C  A  A  G  T  G  G  A  T  G  A  T  T  T  T  C  , and reverse, A  C  A  G  T  A  G  G  C  A  T  T  A-
T  T  G  G  T  C  T  G  ; GAPDH forward, T  G  A  A  G  G  T  C  G  G  A  G  T  C  A  A  C  G  G  A  T  T  T  G  G  T  , 
and reverse, C  A  T  G  T  G  G  G  C  C  A  T  G  A  G  G  T  C  C  A  C  C  A  C  ; IGF-1 forward, G  T  G-
G  A  T  G  C  T  C  T  T  C  A  G  T  T  C  G  T  , and reverse, A  C  A  C  T  C  C  T  A  A  A  G  A  C  G  A  T  G  T  T  ; IL4 
forward, A  A  C  C  C  C  C  A  G  C  T  A  G  T  T  G  T  C  A  T  C  C  T  G  , and reverse, C  A  T  C  G  A  A  A-
A  G  C  C  C  G  A  A  A  G  A  G  T  C  T  C  ; MLC3F forward, G  A  T  C  A  C  C  T  T  A  A  G  T  C  A  G  G  T  , 
and reverse, G  C  A  A  C  G  C  T  T  C  T  A  C  C  T  C  T  T  ; myostatin forward, A  G  C  C  T  G  A  A  T-
C  C  A  A  C  T  T  A  G  G  C  , and reverse, G  G  T  G  C  A  C  A  A  G  A  T  G  A  G  T  A  T  G  C  .
Plasmids and transfections
500 bp of the rat follistatin proximal promoter linked to the luciferase was 
derived from the 2.8-Kb rat follistatin promoter–luciferase construct 
(Bilezikjian et al., 2001). Id, VIVIT, and A-CREB expression vectors have 
been described before (Iezzi et al., 2004). The transfections were per-
formed with the FuGENE6 reagent (Roche). Luciferase assay on cell lysates 
was performed as described previously (Iezzi et al., 2004).
Statistical analysis
The results are expressed as means ± SEM. Statistical analysis was per-
formed using a two-tailed t test for unpaired variables. Asterisks and 
crosses in the ﬁ  gure panels refer to statistical probabilities, measured in the 
various experimental conditions as detailed in the ﬁ  gure legends. Statistical 
probability values of <0.05 were considered signiﬁ  cant.
Image acquisition and manipulation
Images in ﬂ  uorescence have been taken on a microscope (Eclipse E600; 
Nikon; plan ﬂ  uor 4×/0.13, 10×/0.33, 20×/0.50, and 40×/0.75) and 
phase-contrast images of embryos on stereomicroscope (SMZ1500; Nikon; 
high-resolution plan apochromatic 1× WD54, eyepiece lens CW 10×/22). 
All images were acquired using a digital camera (DXM1200; Nikon) and 
the acquisition software ACT-1 (Nikon), imaging medium, PBS buffer, and 
room temperature. Images were assembled in panels using Photoshop 7.0 
(Adobe). Images showing double ﬂ  uorescence (FITC and Hoechst) were ﬁ  rst 
separately acquired using the different appropriate ﬁ  lters and then merged 
with Photoshop 7.0.
Online supplemental material
Fig. S1 shows the densitometric quantiﬁ   cation of RT-PCR and Western 
blots analysis shown in Fig. 4. Fig. S2 shows that inhibition of follistatin 
expression by RNA interference abolishes the effect of NO/cGMP 
on fusion-induced muscle hypertophy in C2C12. Fig. S3 shows that 
the NO/cGMP effect on follistatin induction is speciﬁ   c to skeletal myo-
blasts. Supplemental text describes the methods used in the RNA inter-
ference and in the culture of cardiomyocytes and of C3H10 T1/2, NIH 
3T3, P19, and D351 cells. Online supplemental material is available at 
http://  www.  jcb.  org/  cgi/  content/  full/  jcb.  200507083/  DC1.
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